Research tools
Biomarker articles covering signals used to study, predict, monitor, or measure Crohn's disease and IBD activity or treatment response.
Page 4 of 6 · 242 articles
Identifies gene and microbiome patterns linked to progression from inflammation to irreversible bowel fibrosis in Crohn’s disease, which could eventually help predict who is at higher risk and inform prevention...
Distinct circulating immune signatures could help differentiate active UC from CD and suggest disease-specific pathways that might guide future biomarkers or therapies.
If validated, blood microRNAs could become noninvasive biomarkers to help track inflammation and predict biochemical response to infliximab or vedolizumab in Crohn’s disease, complementing CRP and fecal calprotectin.
Fibrosis (irreversible bowel scarring) is a major cause of surgery in Crohn’s disease. This study points to molecular and microbiome patterns that may help predict or distinguish fibrosis from active inflammation, which...
Fibrosis (irreversible bowel scarring) is a major cause of surgery in Crohn’s disease. Identifying molecular and microbial markers tied to fibrosis could eventually help predict who’s at higher risk and guide earlier,...
The work points to measurable molecular and microbial patterns that may help distinguish treatable inflammation from progressive fibrosis and suggests AI could aid in building predictive tools from limited samples —...
The probe targets azoreductase-driven hypoxia, a mechanism linked to ulcerative colitis and other hypoxia-associated diseases; a reliable real-time imaging method could help research and eventually guide treatments.
The study links shared gene-expression patterns between IBD and ankylosing spondylitis and highlights STAT3 as a potential shared biomarker or therapeutic target, which could be relevant for understanding overlapping...
Researchers used genetics plus single-cell sequencing and ELISA to prioritize plasma protein ratios that may causally relate to ulcerative colitis. If validated in larger studies, such biomarkers could help with...
If you or a loved one follow emerging IBD treatments, this update signals a new PALI-2108 program moving into Phase 2 for ulcerative colitis and planned Phase 2 testing in Crohn’s disease, plus a company focus on...
Researchers found antisense RNA activity in gut microbes that tracks with active inflammation in IBD and with faecal calprotectin — suggesting a new microbial signal that might help understand or monitor disease...
RDW is a cheap, routinely measured blood parameter; if it reliably reflects IBD presence or activity, it could be an easy additional tool to help detect flares or support assessment without extra testing.
If you have IBD and take biologic therapy plus other medicines, inflammation and anti-cytokine treatment may change how your other drugs are metabolized. This review discusses ways researchers are trying to predict and...
A blood antibody (anti-integrin αvβ6) was associated with relapse risk in UC and may help predict who stays in long-term remission, which could affect monitoring and treatment planning.
The study suggests blood metabolite patterns differ by biologic therapy and identifies candidate biomarkers that might help develop less-invasive monitoring tools for inflammation and treatment effects in Crohn’s...
Researchers and clinicians are exploring how fucose metabolism affects gut barrier function, immunity, and microbiota — processes central to IBD and colorectal cancer. If validated, fucosylation biomarkers or treatments...
Researchers and clinicians looking for blood- or tissue-based molecular tests for IBD may find these integrated transcriptomic analyses useful because they identify candidate diagnostic biomarkers and highlight shared...
Early, noninvasive biomarkers could help detect ulcerative colitis and related colorectal cancer risk sooner. This study identifies four serum-accessible proteins with promising diagnostic accuracy in the reported...
PSC occurring with IBD changes cancer risk and surveillance needs: patients can have extensive but asymptomatic colitis and a higher colorectal and biliary cancer risk. The review outlines gaps in diagnosis, monitoring,...
This review examines a noninvasive neuromodulation strategy (ta‑VNS) that might modulate immune and gut‑barrier biomarkers in IBD and could become an adjunctive therapy if validated in trials. Patients and clinicians may...
This registered Phase 2/3 program is evaluating guselkumab (an IL‑23 inhibitor) for moderate–severe Crohn's disease and could expand treatment options if trials show benefit and safety. The studies include clinical and...
Environmental exposures from agricultural chemicals may affect the gut microbiome and intestinal inflammation, which could be one factor influencing IBD risk or flares. Understanding these links could point to preventive...
Intestinal fibrosis is a serious complication of long-standing ulcerative colitis. Identifying NET-related biomarkers (IL1RN, MUC1, SERPINA1) could help researchers develop better diagnostic tools or treatments targeting...
Identifying an RNF213-marked Treg subset may help researchers understand immune mechanisms active in UC and could lead to new biomarker or therapeutic targets in the future.
RDW is part of a routine complete blood count and, if reliably associated with IBD activity, could offer a low-cost, widely available adjunctive biomarker for detecting disease and monitoring activity.
If validated, epithelial CXCL1 could become a tissue biomarker that helps track remission specifically in ulcerative colitis and serve as a functional readout for epithelial-directed therapies tested in patient-derived...
The review suggests RDW, an inexpensive and widely available blood test parameter, is higher in IBD and correlates with disease activity—meaning it might help clinicians monitor disease alongside other tests.
The study identifies specific induction exposure targets and biomarkers tied to higher chances of deep remission at 12 months in children on anti-TNF therapy, which could inform earlier dose optimization to improve...
This matters because identifying microbiome patterns linked to infliximab response could help predict which children with IBD are more likely to benefit from the drug and guide personalized treatment decisions in the...
The study suggests quality-of-life and patient-reported measures can reveal a subgroup of UC patients in clinical remission who nevertheless have higher relapse risk, which could help personalize monitoring and care.
Sarcopenia is common in Crohn's disease and is linked to worse outcomes; a simple GNRI-based prediction tool could help identify at-risk patients without routine CT scanning.
Researchers report links between copper-driven cell death pathways and IBD biology; identifying cuproptosis-related biomarkers or drugs could open new diagnostic or therapeutic avenues for people with Crohn's disease or...
If you or your clinician are considering dietary therapy like the CDED for Crohn's disease, microbiome features at baseline may influence who achieves sustained remission. Understanding these links could help personalize...
Risk-prediction tools like CDPATH™ could help people with Crohn’s disease and their doctors identify higher or lower short-term risk of complications and guide treatment conversations. This study tests how the tool...
If fecal GP2 reliably reflects UC activity and microbial changes, it could become a noninvasive marker to track inflammation or to study disease mechanisms that differ between UC and CD.
Identifying patients at higher risk of hospitalization earlier could help clinicians target monitoring or treatment changes before clinical deterioration. Standard lab reference ranges may miss meaningful within-person...
FUT2 connects genetics, mucosal sugars, and the gut microbiome — pathways that could help explain why some people with IBD have different microbiomes or disease risk. If validated in trials, FUT2-targeted or...
Exercise is a low-cost, accessible intervention that may improve quality of life and reduce symptoms in people with IBD. This pooled analysis suggests some exercise types — especially regular continuous aerobic exercise...
This research links molecular subtypes of ulcerative colitis to infliximab (anti-TNF) response using an interpretable machine-learning method, which could help identify which patients are more or less likely to respond...
Oxidative stress may help explain some biological drivers of inflammation in Crohn’s disease and ulcerative colitis and could become a target for biomarkers or therapies in the future. Right now, the evidence is...
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
Blood markers that correlate with endoscopic healing could help track inflammation noninvasively and may reduce the frequency of endoscopy if validated. For people with IBD, better blood-based tools could make monitoring...
The study describes a new urine-based fluorescent biosensor that detected inflamed intestinal sites and tracked treatment response earlier and more sensitively than fecal calprotectin in a mouse model of IBD, which could...
This study suggests that subgrouping autoimmune diseases by a Traditional Chinese Medicine phenotype (Dampness ZHENG) corresponds to distinct T‑ and B‑cell receptor patterns.
PSC can progress to cirrhosis and cholangiocarcinoma; circulating multi-omic signatures that track severity and cancer-associated changes could help explain disease biology and lead to biomarkers for risk stratification...
This review suggests a new way to think about IBD relapse and disease persistence: persistent changes in innate immune cells (trained immunity) could maintain gut inflammation even when adaptive immune targets are...
Bowel urgency is a common symptom that may predict higher risk of treatment escalation, hospitalization, or surgery in UC even when bleeding and stool frequency look controlled. Better assessment of urgency in clinic...
The review highlights how microbial metabolites, epigenetic regulation, and mitochondrial metabolism interact to shape inflammation and barrier function in IBD. Understanding these links could help identify new...
